Skip to content

Exploring the corticomuscular coupling mechanism of rTMS combined with task-oriented soft robot glove training to improve upper limb function in stroke patients

Exploring the corticomuscular coupling mechanism of rTMS combined with task-oriented soft robot glove training to improve upper limb function in stroke patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400090007
Enrollment
Unknown
Registered
2024-09-23
Start date
2024-10-01
Completion date
Unknown
Last updated
2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stroke

Interventions

Study 1: Task-oriented soft robot glove training +rTMS group:Age-matched healthy subjects were treated with soft robot glove therapy and rTMS therapy in sequence.
Study 1: TMS+Task-oriented soft robot glove training group:Age-matched healthy subjects were treated with rTMS and soft robotic gloves sequentially.
Study 1: rTMS +Task-oriented soft robot glove training group:Stroke patients who met the inclusion and exclusion criteria were treated with rTMS and soft robotic gloves in sequence.
Study 1: Task-oriented soft robot glove training +rTMS group:Stroke patients who met the inclusion and exclusion criteria were treated with soft robotic gloves rTMS in sequence.
Study 2: Combination treatment group:rTMS and soft robotic gloves in sequence according to results of study I.
Study 2: rTMS treatment group:rTMS treatment.
Study 2: sham rTMS+Task-oriented soft robot glove training group:sham rTMS+soft robot glove training

Sponsors

Zhongda Hospital affiliated to Southeast University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Inclusion criteria for study I: (1) Inclusion criteria for healthy subjects: ? Aged 18-75 years (inclusive); ? Edinburgh Handedness Scale was assessed as right-handedness; ? Good health condition, no cerebrovascular disease, no brain and spinal cord injury, no neuromuscular disease or injury, no tinnitus, insomnia and other symptoms; ? Agree to participate in the experiment and sign the informed consent; (2) Inclusion criteria for stroke patients: ? Age 18-75 years old (inclusive); (2) First stroke diagnosed by computed tomography (CT) and/or MRI; (3) The course of stroke from 1 month to 6 months after onset, Brunnstrom stage II to V; ? Good cognitive function, MMSE score =21, can understand simple commands and cooperate with treatment, can tolerate 1h-1.5h test and evaluation; ? Sign informed consent. 2. Inclusion criteria for Study 2: Inclusion criteria for stroke patients: ? Age 18-75 years old (inclusive); (2) First stroke diagnosed by computed tomography (CT) and/or MRI; (3) The course of stroke from 1 month to 6 months after onset, Brunnstrom stage II to V; ? Good cognitive function, MMSE score =21, can understand simple commands and cooperate with treatment, can tolerate 1h-1.5h test and evaluation; ? Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Exclusion criteria for study 1: Exclusion criteria for healthy subjects: (1) Clinical imaging indicated finger and wrist joint lesions; ? History of epilepsy and family history of epilepsy; ? Other clinical studies are being conducted; ? Other reasons can not cooperate with the evaluation and detection. Exclusion criteria for stroke patients: ? had intracerebral implants or metal, cochlear implants, cardiac pacemakers, etc.; ? Patients with severe upper limb spasm, modified Ashworth scale > grade 2; (3) Epilepsy patients and those who take drugs that can cause epilepsy, have serious heart, liver, kidney diseases (such as myocardial infarction, heart failure, liver cancer and uremia) or infectious diseases; Participate in other clinical studies. 2. Exclusion criteria for study 2: Exclusion criteria for stroke patients: ? had intracerebral implants or metal, cochlear implants, cardiac pacemakers, etc.; ? Patients with severe upper limb spasm, modified Ashworth scale > grade 2; (3) Epilepsy patients and those who take drugs that can cause epilepsy, have serious heart, liver, kidney diseases (such as myocardial infarction, heart failure, liver cancer and uremia) or infectious diseases; Participate in other clinical studies.

Design outcomes

Primary

MeasureTime frame
Study 1: corticomuscular coupling;Study 2: Fugl-Meyer assessment for upper extremity;

Secondary

MeasureTime frame
Study 1: Median nerve F wave;Study 1: Electrophysiological indicators (Ipsilateral silent period, motor evoked potential, MEP recruitment curve);Study 1: Nine Hole Peg Test;Study 2: corticomuscular coupling;Study 2: Upper limb motor performance (box and blocks test, Wolf Motor Function Test, Nine Hole Peg Test, Action Research Arm Test);Study 2: Muscle strength and spasticity (manual muscle test, surface electromyography, grip strength,Joint range of motion, Modified Ashworth Scale, F-wave, H/M ratio);Study 2: Brunnstrom Recovery Stages for Upper Limb?;Study 2: Cortical excitability (MEP, MEP recruitment curve, and cortical silence period);Study 2: Assessment of activities of daily living (Modified Barthel Index, Functional independence measure, Motor activity log);Study 2: Sensory evoked potential (Semmes-Weinstein monofilament test, and Nottingham Sensory Assessment);Study 2: Imaging evaluation (structural MRI, fMRI, DTI collection);

Countries

China

Contacts

Public ContactWenli Chen

Zhongda Hospital of Southeast University

banlilizhi@163.com+86 25 8328 5165

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 22, 2026